This trial will test a new drug to treat two types of brain inflammation: NMDAR and LGI1 encephalitis.
- LGI1 Autoimmune Encephalitis
- NMDA Receptor Autoimmune Encephalitis
2 Primary · 8 Secondary · Reporting Duration: From Week 52 up to 2 years
Side Effects for
4 Treatment Groups
LGI1 AIE cohort
1 of 4
NMDAR autoimmune encephalitis (AIE) cohort
1 of 4
NMDAR autoimmune encephalitis (AIE) Placebo cohort
1 of 4
LGI1 AIE Placebo cohort
1 of 4
152 Total Participants · 4 Treatment Groups
Primary Treatment: LGI1 AIE cohort · Has Placebo Group · Phase 3
Who is running the clinical trial?
Age Any Age · All Participants · 7 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
- 2022. "A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) Or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05503264.
Frequently Asked Questions
How does the LGI1 AIE cohort impact patient safety?
"The LGI1 AIE cohort has ample evidence of its efficacy, and multiple studies have demonstrated its safety; therefore, we rate it a 3 on the risk spectrum." - Anonymous Online Contributor
Are there any vacant vacancies available in this medical trial?
"Affirmative, clinicaltrials.gov is hosting the details of this research which initially went public on September 27th 2022 and had its most recent update on November 8th 2022. 152 patients need to be registered at a single medical facility." - Anonymous Online Contributor
How many participants have been admitted to this clinical trial thus far?
"Affirmative. According to clinicaltrials.gov, this research trial is actively recruiting and was initially posted on September 27th 2022; the posting has been recently revised as of November 8th 2022. The study requires 152 participants from 1 medical centre." - Anonymous Online Contributor